BMS has announced that Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) was approved by European Union for the treatment of relapsed and refractory multiple myeloma. The drug is approved in the patients who failed atleast two treatments including lenalidomide and a proteasome inhibitor (PI).
The approval is based on the ELOQUENT-3 trial, in whichEmpliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) was compared with pomalidomide and low-dose dexamethasone alone. Progression-free survival and overall response was significant in patients taking Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd). The progression free survival was 10.25 months in Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) compared to 4.67 months in patients administered with pomalidomide and low-dose dexamethasone (EPd).
The drug is already approved in the Europe for patients who failed one therapy. The drug is approved in the United States by FDA adult patients with multiplemyeloma who have received at least prior therapies.
Comments